Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity.

Garrido G, Schrand B, Rabasa A, Levay A, D'Eramo F, Berezhnoy A, Modi S, Gefen T, Marijt K, Doorduijn E, Dudeja V, van Hall T, Gilboa E.

Nat Commun. 2019 Aug 21;10(1):3773. doi: 10.1038/s41467-019-11728-2.

2.

TEIPP peptides: exploration of unTAPped cancer antigens.

Marijt KA, Van Der Burg SH, van Hall T.

Oncoimmunology. 2019 May 13;8(8):1599639. doi: 10.1080/2162402X.2019.1599639. eCollection 2019.

3.

Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?

van Weeghel C, Wierenga APA, Versluis M, van Hall T, van der Velden PA, Kroes WGM, Pfeffer U, Luyten GPM, Jager MJ.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1127. doi: 10.3390/cancers11081127.

4.

Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling.

Marijt KA, Sluijter M, Blijleven L, Tolmeijer SH, Scheeren FA, van der Burg SH, van Hall T.

J Immunother Cancer. 2019 Jun 13;7(1):152. doi: 10.1186/s40425-019-0627-8.

5.

A herpesvirus encoded Qa-1 mimic inhibits natural killer cell cytotoxicity through CD94/NKG2A receptor engagement.

Wang X, Piersma SJ, Nelson CA, Dai YN, Christensen T, Lazear E, Yang L, Sluijter M, van Hall T, Hansen TH, Yokoyama WM, Fremont DH.

Elife. 2018 Dec 21;7. pii: e38667. doi: 10.7554/eLife.38667.

6.

Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F.

JCI Insight. 2018 Dec 6;3(23). pii: 124507. doi: 10.1172/jci.insight.124507.

7.

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T.

Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29.

PMID:
30503208
8.

Arming oncolytic reovirus with GM-CSF gene to enhance immunity.

Kemp V, van den Wollenberg DJM, Camps MGM, van Hall T, Kinderman P, Pronk-van Montfoort N, Hoeben RC.

Cancer Gene Ther. 2019 Sep;26(9-10):268-281. doi: 10.1038/s41417-018-0063-9. Epub 2018 Nov 23.

PMID:
30467340
9.

High FcγR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy.

Benonisson H, Sow HS, Breukel C, Claassens J, Brouwers C, Linssen MM, Fransen MF, Sluijter M, Ossendorp F, van Hall T, Verbeek JS.

J Immunol. 2018 Dec 15;201(12):3741-3749. doi: 10.4049/jimmunol.1800700. Epub 2018 Nov 5.

PMID:
30397036
10.

CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.

Benonisson H, Altıntaş I, Sluijter M, Verploegen S, Labrijn AF, Schuurhuis DH, Houtkamp MA, Verbeek JS, Schuurman J, van Hall T.

Mol Cancer Ther. 2019 Feb;18(2):312-322. doi: 10.1158/1535-7163.MCT-18-0679. Epub 2018 Oct 31.

PMID:
30381448
11.

FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.

Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS.

Int J Cancer. 2019 Jan 15;144(2):345-354. doi: 10.1002/ijc.31899. Epub 2018 Nov 12.

PMID:
30259976
12.

Identification of non-mutated neoantigens presented by TAP-deficient tumors.

Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T.

J Exp Med. 2018 Sep 3;215(9):2325-2337. doi: 10.1084/jem.20180577. Epub 2018 Aug 16.

13.

Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.

de Lange MJ, Nell RJ, Lalai RN, Versluis M, Jordanova ES, Luyten GPM, Jager MJ, van der Burg SH, Zoutman WH, van Hall T, van der Velden PA.

Mol Cancer Res. 2018 Dec;16(12):1902-1911. doi: 10.1158/1541-7786.MCR-18-0114. Epub 2018 Aug 9.

PMID:
30093564
14.

FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines.

Benonisson H, Sow HS, Breukel C, Claassens JWC, Brouwers C, Linssen MM, Redeker A, Fransen MF, van Hall T, Ossendorp F, Arens R, Verbeek S.

Oncotarget. 2018 Jun 29;9(50):29392-29402. doi: 10.18632/oncotarget.25630. eCollection 2018 Jun 29.

15.

TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers.

Marijt KA, Doorduijn EM, van Hall T.

Mol Immunol. 2018 Apr 4. pii: S0161-5890(18)30108-1. doi: 10.1016/j.molimm.2018.03.029. [Epub ahead of print]

16.

A Restricted Role for FcγR in the Regulation of Adaptive Immunity.

Fransen MF, Benonisson H, van Maren WW, Sow HS, Breukel C, Linssen MM, Claassens JWC, Brouwers C, van der Kaa J, Camps M, Kleinovink JW, Vonk KK, van Heiningen S, Klar N, van Beek L, van Harmelen V, Daxinger L, Nandakumar KS, Holmdahl R, Coward C, Lin Q, Hirose S, Salvatori D, van Hall T, van Kooten C, Mastroeni P, Ossendorp F, Verbeek JS.

J Immunol. 2018 Apr 15;200(8):2615-2626. doi: 10.4049/jimmunol.1700429. Epub 2018 Mar 9.

17.

The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability.

Hafstrand I, Doorduijn EM, Sun R, Talyzina A, Sluijter M, Pellegrino S, Sandalova T, Duru AD, van Hall T, Achour A.

J Immunol. 2018 Apr 15;200(8):2860-2868. doi: 10.4049/jimmunol.1700228. Epub 2018 Mar 5.

18.

T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1b with TAP-Independent Peptides Are Semi-Invariant Lymphocytes.

Doorduijn EM, Sluijter M, Querido BJ, Seidel UJE, Oliveira CC, van der Burg SH, van Hall T.

Front Immunol. 2018 Jan 25;9:60. doi: 10.3389/fimmu.2018.00060. eCollection 2018.

19.

T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.

Doorduijn EM, Sluijter M, Marijt KA, Querido BJ, van der Burg SH, van Hall T.

Oncoimmunology. 2017 Nov 20;7(3):e1382793. doi: 10.1080/2162402X.2017.1382793. eCollection 2018.

20.

The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.

Versluis MAC, Marchal S, Plat A, de Bock GH, van Hall T, de Bruyn M, Hollema H, Nijman HW.

Eur J Cancer. 2017 Nov;86:285-295. doi: 10.1016/j.ejca.2017.09.008. Epub 2017 Oct 20.

PMID:
29059634
21.

PD-L1 immune suppression in cancer: Tumor cells or host cells?

Kleinovink JW, van Hall T, Ossendorp F, Fransen MF.

Oncoimmunology. 2017 May 12;6(7):e1325982. doi: 10.1080/2162402X.2017.1325982. eCollection 2017.

22.

CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy.

Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, Ossendorp F, van der Burg SH, van Hall T.

Cancer Immunol Res. 2017 Aug;5(8):642-653. doi: 10.1158/2326-6066.CIR-16-0334. Epub 2017 Jun 21.

23.

Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.

Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG.

Cancer Immunol Res. 2017 Jul;5(7):535-546. doi: 10.1158/2326-6066.CIR-16-0309. Epub 2017 May 23.

24.

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.

Kleinovink JW, Marijt KA, Schoonderwoerd MJA, van Hall T, Ossendorp F, Fransen MF.

Oncoimmunology. 2017 Feb 21;6(4):e1294299. doi: 10.1080/2162402X.2017.1294299. eCollection 2017.

25.

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Gezgin G, Dogrusöz M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, Walter V, Verdijk RM, van Hall T, van der Burg SH, Jager MJ.

Cancer Immunol Immunother. 2017 Jul;66(7):903-912. doi: 10.1007/s00262-017-1991-1. Epub 2017 Apr 8.

26.

Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes.

van Essen TH, van Pelt SI, Bronkhorst IH, Versluis M, Némati F, Laurent C, Luyten GP, van Hall T, van den Elsen PJ, van der Velden PA, Decaudin D, Jager MJ.

PLoS One. 2016 Oct 20;11(10):e0164292. doi: 10.1371/journal.pone.0164292. eCollection 2016.

27.

Vaccines for established cancer: overcoming the challenges posed by immune evasion.

van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ.

Nat Rev Cancer. 2016 Apr;16(4):219-33. doi: 10.1038/nrc.2016.16. Epub 2016 Mar 11. Review.

PMID:
26965076
28.

The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR Conformer.

Hafstrand I, Doorduijn EM, Duru AD, Buratto J, Oliveira CC, Sandalova T, van Hall T, Achour A.

J Immunol. 2016 Mar 1;196(5):2327-34. doi: 10.4049/jimmunol.1502249. Epub 2016 Jan 22.

29.

The urgent need to recover MHC class I in cancers for effective immunotherapy.

Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T.

Curr Opin Immunol. 2016 Apr;39:44-51. doi: 10.1016/j.coi.2015.12.007. Epub 2016 Jan 18. Review.

30.

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.

Doorduijn EM, Sluijter M, Querido BJ, Oliveira CC, Achour A, Ossendorp F, van der Burg SH, van Hall T.

J Clin Invest. 2016 Feb;126(2):784-94. doi: 10.1172/JCI83671. Epub 2016 Jan 19.

31.

The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.

Talebian Yazdi M, van Riet S, van Schadewijk A, Fiocco M, van Hall T, Taube C, Hiemstra PS, van der Burg SH.

Oncotarget. 2016 Jan 19;7(3):3477-88. doi: 10.18632/oncotarget.6506.

32.

Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.

de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, van der Burg SH, Luyten GP, van Hall T, Jager MJ, van der Velden PA.

Oncotarget. 2015 Nov 10;6(35):37824-35. doi: 10.18632/oncotarget.5637.

33.

Therapeutic cancer vaccines.

Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH.

J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. Review.

34.

Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome.

Oliveira CC, van Hall T.

Front Immunol. 2015 Jun 5;6:298. doi: 10.3389/fimmu.2015.00298. eCollection 2015. Review.

35.

Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression.

van der Sluis TC, Sluijter M, van Duikeren S, West BL, Melief CJ, Arens R, van der Burg SH, van Hall T.

Cancer Immunol Res. 2015 Sep;3(9):1042-51. doi: 10.1158/2326-6066.CIR-15-0052. Epub 2015 Apr 17. Erratum in: Cancer Immunol Res. 2015 Nov;3(11):1289.

36.

Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase.

Li XL, Sluijter M, Doorduijn EM, Kale SP, McFerrin H, Liu YY, Li Y, Mottamal M, Yao X, Du F, Gu B, Hoang K, Nguyen YH, Taylor N, Stephens CR, van Hall T, Zhang QJ.

PLoS One. 2014 Nov 10;9(11):e108192. doi: 10.1371/journal.pone.0108192. eCollection 2014.

37.

Inhibition of CSF-1R supports T-cell mediated melanoma therapy.

Sluijter M, van der Sluis TC, van der Velden PA, Versluis M, West BL, van der Burg SH, van Hall T.

PLoS One. 2014 Aug 11;9(8):e104230. doi: 10.1371/journal.pone.0104230. eCollection 2014.

38.

Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire.

Oliveira CC, Sluijter M, Querido B, Ossendorp F, van der Burg SH, van Hall T.

Mol Immunol. 2014 Nov;62(1):129-36. doi: 10.1016/j.molimm.2014.06.006. Epub 2014 Jun 28.

PMID:
24983205
39.

New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation.

Oliveira CC, Querido B, Sluijter M, de Groot AF, van der Zee R, Rabelink MJ, Hoeben RC, Ossendorp F, van der Burg SH, van Hall T.

J Immunol. 2013 Oct 15;191(8):4020-8. doi: 10.4049/jimmunol.1301496. Epub 2013 Sep 18.

40.

Proline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptides.

Uchtenhagen H, Abualrous ET, Stahl E, Allerbring EB, Sluijter M, Zacharias M, Sandalova T, van Hall T, Springer S, Nygren PÅ, Achour A.

Eur J Immunol. 2013 Nov;43(11):3051-60. doi: 10.1002/eji.201343456. Epub 2013 Aug 30.

41.

Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, Silva AL, Jiskoot W, van Hall T, van Veelen PA, Janssen G, Franken K, Cruz LJ, Tromp A, Oostendorp J, van der Burg SH, Ossendorp F, Melief CJ.

Eur J Immunol. 2013 Oct;43(10):2554-65. doi: 10.1002/eji.201343324. Epub 2013 Aug 5.

42.

Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.

de Vos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T, Kuijjer ML, van Poelgeest MI, van der Burg SH, Jordanova ES.

Int J Cancer. 2013 Dec 15;133(12):2884-94. doi: 10.1002/ijc.28309. Epub 2013 Jul 5.

43.

Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.

Arens R, van Hall T, van der Burg SH, Ossendorp F, Melief CJ.

Semin Immunol. 2013 Apr;25(2):182-90. doi: 10.1016/j.smim.2013.04.008. Epub 2013 May 21. Review.

PMID:
23706598
44.

Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.

Ly LV, Sluijter M, van der Burg SH, Jager MJ, van Hall T.

J Immunol. 2013 Jan 1;190(1):489-96. doi: 10.4049/jimmunol.1200135. Epub 2012 Nov 30.

45.

Importance of TAP-independent processing pathways.

Oliveira CC, van Hall T.

Mol Immunol. 2013 Sep;55(2):113-6. doi: 10.1016/j.molimm.2012.10.005. Epub 2012 Nov 23. Review.

PMID:
23183105
46.

Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2.

Lampen MH, Hassan C, Sluijter M, Geluk A, Dijkman K, Tjon JM, de Ru AH, van der Burg SH, van Veelen PA, van Hall T.

Mol Immunol. 2013 Jan;53(1-2):126-31. doi: 10.1016/j.molimm.2012.07.009. Epub 2012 Aug 13.

PMID:
22898188
47.

Infiltrating CTLs are bothered by HLA-E on tumors.

Gooden MJ, van Hall T.

Oncoimmunology. 2012 Jan 1;1(1):92-93.

48.

Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.

van Luijn MM, van de Loosdrecht AA, Lampen MH, van Veelen PA, Zevenbergen A, Kester MG, de Ru AH, Ossenkoppele GJ, van Hall T, van Ham SM.

PLoS One. 2012;7(4):e34649. doi: 10.1371/journal.pone.0034649. Epub 2012 Apr 26.

49.

Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity.

van Hall T, van der Burg SH.

Adv Immunol. 2012;114:51-76. doi: 10.1016/B978-0-12-396548-6.00003-2. Review.

PMID:
22449778
50.

Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL.

Durgeau A, El Hage F, Vergnon I, Validire P, de Montpréville V, Besse B, Soria JC, van Hall T, Mami-Chouaib F.

J Immunol. 2011 Dec 1;187(11):5532-9. doi: 10.4049/jimmunol.1102060. Epub 2011 Oct 24.

Supplemental Content

Loading ...
Support Center